Overview

Analysis of the Microbiome in Rosacea

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The skin and gut microbiome of rosacea patients differs from individuals without rosacea and that the microbiome suffers from unique derangements in rosacea patients following antibiotic therapy. This study was proposed to examine microbial signatures of the skin and gut microbiome in patients with moderate to severe rosacea and to identify differences between microbe communities in patients with rosacea and volunteers without rosacea using 16S ribosomal ribonucleic acid (rRNA) polymerase chain reaction (PCR) amplification, sequencing and computational phylogenetics and to assess alterations in the gut and skin microbiota of patients with moderate to severe rosacea in response to varying formulations of antimicrobial treatment.
Phase:
Early Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Treatments:
Doxycycline
Ivermectin